...
首页> 外文期刊>Archives of virology >Efficiency of bacteriophage therapy against Cronobacter sakazakii in Galleria mellonella (greater wax moth) larvae.
【24h】

Efficiency of bacteriophage therapy against Cronobacter sakazakii in Galleria mellonella (greater wax moth) larvae.

机译:噬菌体Mellonella(更大的蜡蛾)幼虫菌对丘亚杆菌的噬菌体治疗效率。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cronobacter sakazakii, an opportunistic pathogen found in milk-based powdered infant formulae, has been linked to meningitis in infants, with high fatality rates. A set of phages from various environments were purified and tested in vitro against strains of C. sakazakii. Based on host range and lytic activity, the T4-like phage vB_CsaM_GAP161, which belongs to the family Myoviridae, was selected for evaluation of its efficacy against C. sakazakii. Galleria mellonella larvae were used as a whole-animal model for pre-clinical testing of phage efficiency. Twenty-one Cronobacter strains were evaluated for lethality in G. mellonella larvae. Different strains of C. sakazakii caused 0 to 98% mortality. C. sakazakii 3253, with an LD50 dose of ~2.0×10(5) CFU/larva (24 h, 37 °C) was selected for this study. Larvae infected with a dose of 5×LD50 were treated with phage GAP161 (MOI=8) at various time intervals. The mortality rates were as high as 100% in the groups injected with bacteria only, compared to 16.6% in the group infected with bacteria and treated with phage. Phage GAP161 showed the best protective activity against C. sakazakii when the larvae were treated prior to or immediately after infection. The results obtained with heat-inactivated phage proved that the survival of the larvae is not due to host immune stimulation. These results suggest that phage GAP161 is potentially a useful control agent against C. sakazakii. In addition, G. mellonella may be a useful whole-animal model for pre-screening phages for efficacy and safety prior to clinical evaluation in mammalian models.
机译:Cronobacter Sakazakii是一种在牛奶基粉末婴儿配方中发现的机会主义病原体,与婴儿的脑膜炎有关,具有高死亡率。纯化来自各种环境的一组噬菌体,并在体外施用菌株C. Sakazakii。基于宿主范围和裂变活动,选择属于Myoviridae的T4样噬菌体VB_CSAM_GAP161,用于评估其对C. Sakazakii的功效。 Galleria Mellonella幼虫被用作噬菌体效率前临床测试的全动物模型。在G.Mellonella幼虫中评价了二十一粒ronobacter菌株。不同的C. Sakazakii菌株引起了0至98%的死亡率。 C. Sakazakii 3253,选择LD50剂量〜2.0×10(5)CFU /幼虫(24小时,37℃),用于本研究。以各个时间间隔用噬菌体间隙161(MOI = 8)处理用5×LD50感染的幼虫。在注射细菌的组中,死亡率高达100%,而含有细菌的组和用噬菌体治疗的组中的16.6%。噬菌体GAP161在感染后或在感染后立即进行幼虫时,对C. Sakazaii进行了最佳保护活性。用热灭活噬菌体获得的结果证明,幼虫的存活率不是由于宿主免疫刺激。这些结果表明,噬菌体间隙161可能是针对C. Sakazakii的有用控制剂。此外,G.Mellonella可以是用于在哺乳动物模型中临床评估之前进行疗效和安全性的疗效和安全性的有用的全动物模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号